Chongqing Zhifei Biological Products Co., Ltd. (300122.SZ)
CNY 18.84
(0.48%)
CNY 18.84
(0.48%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 18.49 Billion CNY | 34.36% |
| 2022 | 13.76 Billion CNY | 11.12% |
| 2021 | 12.39 Billion CNY | 77.85% |
| 2020 | 6.96 Billion CNY | 34.1% |
| 2019 | 5.19 Billion CNY | 97.59% |
| 2018 | 2.62 Billion CNY | 125.04% |
| 2017 | 1.16 Billion CNY | 520.77% |
| 2016 | 188.21 Million CNY | -11.39% |
| 2015 | 212.4 Million CNY | -17.26% |
| 2014 | 256.71 Million CNY | 29.26% |
| 2013 | 198.6 Million CNY | 41.62% |
| 2012 | 140.23 Million CNY | -4.1% |
| 2011 | 146.22 Million CNY | 116.35% |
| 2010 | 67.58 Million CNY | 1.89% |
| 2009 | 66.33 Million CNY | -46.09% |
| 2008 | 123.04 Million CNY | -14.71% |
| 2007 | 144.26 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 22.26 Billion CNY | -4.51% |
| 2024 Q1 | 20.9 Billion CNY | 13.01% |
| 2024 Q2 | 23.31 Billion CNY | 11.55% |
| 2023 Q4 | 18.49 Billion CNY | -4.18% |
| 2023 Q1 | 16.97 Billion CNY | 23.29% |
| 2023 FY | 18.49 Billion CNY | 34.36% |
| 2023 Q2 | 20.16 Billion CNY | 18.79% |
| 2023 Q3 | 19.3 Billion CNY | -4.26% |
| 2022 Q3 | 13.92 Billion CNY | -2.32% |
| 2022 Q2 | 14.25 Billion CNY | 22.34% |
| 2022 FY | 13.76 Billion CNY | 11.12% |
| 2022 Q1 | 11.65 Billion CNY | -5.96% |
| 2022 Q4 | 13.76 Billion CNY | -1.12% |
| 2021 FY | 12.39 Billion CNY | 77.85% |
| 2021 Q3 | 11.37 Billion CNY | 11.82% |
| 2021 Q4 | 12.39 Billion CNY | 8.91% |
| 2021 Q2 | 10.17 Billion CNY | 28.12% |
| 2021 Q1 | 7.94 Billion CNY | 13.99% |
| 2020 Q2 | 7.23 Billion CNY | -2.04% |
| 2020 Q4 | 6.96 Billion CNY | -17.85% |
| 2020 FY | 6.96 Billion CNY | 34.1% |
| 2020 Q1 | 7.38 Billion CNY | 42.07% |
| 2020 Q3 | 8.48 Billion CNY | 17.29% |
| 2019 Q2 | 4.54 Billion CNY | 22.08% |
| 2019 Q4 | 5.19 Billion CNY | -9.58% |
| 2019 FY | 5.19 Billion CNY | 97.59% |
| 2019 Q1 | 3.72 Billion CNY | 41.59% |
| 2019 Q3 | 5.74 Billion CNY | 26.42% |
| 2018 Q3 | 2.41 Billion CNY | 16.49% |
| 2018 FY | 2.62 Billion CNY | 125.04% |
| 2018 Q4 | 2.62 Billion CNY | 8.74% |
| 2018 Q2 | 2.07 Billion CNY | 25.72% |
| 2018 Q1 | 1.65 Billion CNY | 41.31% |
| 2017 Q2 | 550.63 Million CNY | 352.65% |
| 2017 Q3 | 715.86 Million CNY | 30.01% |
| 2017 Q4 | 1.16 Billion CNY | 63.21% |
| 2017 FY | 1.16 Billion CNY | 520.77% |
| 2017 Q1 | 121.64 Million CNY | -35.37% |
| 2016 Q2 | 159.74 Million CNY | -5.3% |
| 2016 Q4 | 188.21 Million CNY | 38.95% |
| 2016 FY | 188.21 Million CNY | -11.39% |
| 2016 Q3 | 135.45 Million CNY | -15.21% |
| 2016 Q1 | 168.69 Million CNY | -20.58% |
| 2015 Q3 | 162.43 Million CNY | -17.56% |
| 2015 FY | 212.4 Million CNY | -17.26% |
| 2015 Q1 | 206.05 Million CNY | -19.73% |
| 2015 Q2 | 197.03 Million CNY | -4.38% |
| 2015 Q4 | 212.4 Million CNY | 30.76% |
| 2014 Q4 | 256.71 Million CNY | 50.64% |
| 2014 Q2 | 191.57 Million CNY | 17.56% |
| 2014 Q1 | 162.95 Million CNY | -17.95% |
| 2014 FY | 256.71 Million CNY | 29.26% |
| 2014 Q3 | 170.41 Million CNY | -11.04% |
| 2013 Q3 | 143.85 Million CNY | -13.94% |
| 2013 Q1 | 141.68 Million CNY | 1.04% |
| 2013 FY | 198.6 Million CNY | 41.62% |
| 2013 Q4 | 198.6 Million CNY | 38.06% |
| 2013 Q2 | 167.16 Million CNY | 17.98% |
| 2012 Q3 | 209.91 Million CNY | 16.93% |
| 2012 Q4 | 140.23 Million CNY | -33.2% |
| 2012 FY | 140.23 Million CNY | -4.1% |
| 2012 Q2 | 179.52 Million CNY | -16.89% |
| 2012 Q1 | 216.02 Million CNY | 47.73% |
| 2011 Q3 | 135.68 Million CNY | -11.92% |
| 2011 Q2 | 154.03 Million CNY | 3.24% |
| 2011 Q1 | 149.2 Million CNY | 120.77% |
| 2011 FY | 146.22 Million CNY | 116.35% |
| 2011 Q4 | 146.22 Million CNY | 7.77% |
| 2010 Q4 | 67.58 Million CNY | 33.81% |
| 2010 FY | 67.58 Million CNY | 1.89% |
| 2010 Q2 | 56.26 Million CNY | 0.0% |
| 2010 Q3 | 50.5 Million CNY | -10.23% |
| 2009 Q4 | 66.33 Million CNY | 0.0% |
| 2009 FY | 66.33 Million CNY | -46.09% |
| 2008 FY | 123.04 Million CNY | -14.71% |
| 2007 FY | 144.26 Million CNY | 0.0% |